Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06706921 · ClinicalTrials.gov registry record · Phase 4

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

A Phase 4 study of Neoplasms and Prostatic Neoplasms, sponsored by VA Greater Los Angeles Healthcare System.

Recruiting
Registry status
Phase 4
Development phase
15
Enrollment target
1
Study location

NCT06706921: Recruiting Phase 4 study of Neoplasms and Prostatic Neoplasms, sponsored by VA Greater Los Angeles Healthcare System.

NCT06706921 is a Phase 4 study of Neoplasms and Prostatic Neoplasms that is actively recruiting participants, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 15 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06706921, a Phase 4 study of Neoplasms and Prostatic Neoplasms, is actively recruiting participants, sponsored by VA Greater Los Angeles Healthcare System.

RECRUITING
Registry status
Phase 4
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid)positron emission tomography/computed tomography , as per standard of care in our institution. All patients further undergo eventual follow-up prostate-specific membrane antigen positron emission tomography (PSMA PET) after the 2nd, 4th, and 6th LuPSMA RLT cycle. In this prospective study, an18F-Fluciclovine positron emission tomography/computed tomography ( Axumin PET/CT )will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles. Axumin PET/CT will be acquired within 7 days from the PSMA PET. This study is open to Veterans only.

Primary Outcome

Whole-body and lesion-level SUVmean, SUVmax. SUVmax, or maximum standardized uptake value, is a measurement used in positron emission tomography (PET) scans to quantify how much glucose a tumor is metabolizing.

Conditions Studied

Neoplasms Prostatic Neoplasms Metastatic Prostate Cancer Neoplasms by Site Urogenital Neoplasms Prostatic Neoplasms, Castration-Resistant Genital Diseases, Male Prostatic Diseases Male Urogenital Diseases Urogenital Diseases, Male

Interventions

  • DRUG 18F-Fluciclovine PET/CT Scan

Study Locations (1)

California

  • VA Greater Los Angeles Healthcare System - Los Angeles

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-12-15
Est. Completion 2027-11-01
Phase Phase 4
VA Greater Los Angeles Healthcare System

23 total trials

What NCT06706921 shows while recruiting

NCT06706921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower).

The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluciclovine PET/CT Scan is the first listed.

NCT06706921 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06706921 about?

NCT06706921 is a clinical study titled "18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer". This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-...

What is the current status of trial NCT06706921?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2024-12-15. Estimated completion is 2027-11-01.

What conditions does trial NCT06706921 study?

This clinical trial studies the following conditions: Neoplasms, Prostatic Neoplasms, Metastatic Prostate Cancer, Neoplasms by Site, Urogenital Neoplasms.

What interventions are being tested in trial NCT06706921?

The interventions under investigation include: 18F-Fluciclovine PET/CT Scan (DRUG).

Who is sponsoring clinical trial NCT06706921?

This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06706921 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06706921's enrollment target sits among peer trials

15 150th of 158 higher than 8 of 158 other Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06706921

Source: ClinicalTrials.gov NCT06706921, the US trial registry maintained by the National Library of Medicine. NCT06706921 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.